A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Study sponsor: Tempest Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-12Estimated
Enrollment · participants740Estimated
Source updated2025-09-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.